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Abstract
Hepatitis C virus (HCV) is essentially hepatotropic but its manifesta-
tions can extend beyond the liver. It can be associated with autoim-
mune diseases, such as mixed cryoglobulinemia, membranoprolifera-
tive glomerulonephritis, autoimmune thyroiditis, and lymphoprolif-
erative disorders. The mechanisms that trigger these manifestations
are not completely understood. We describe a 48-year-old man with
chronic HCV infection (circulating HCV RNA and moderate hepatitis
as indicated by liver biopsy), cryoglobulinemia, and sensory and
motor peripheral neuropathy. The diagnosis of multineuropathy was
confirmed by clinical examination and electromyographic tests. A
nerve biopsy revealed an inflammatory infiltrate in the perineurial
space and signs of demyelination and axonal degeneration. The
patient had no improvement of neurological symptoms with the use of
analgesics and neuro-modulators. He was then treated with interferon-
α (3 million units subcutaneously, 3 times per week) and ribavirin
(500 mg orally, twice a day) for 48 weeks. Six months after the end of
therapy, the patient had sustained viral response (negative HCV RNA)
and remission of neurological symptoms, but cryoglobulins remained
positive. A review of the literature on the pathogenesis and treatment
of neurological manifestations associated with HCV infection is
presented. This report underscores the need for a thorough evaluation
of HCV-infected patients because of the possibility of extrahepatic
manifestations. Antiviral treatment with interferon and ribavirin can
be effective and should be considered in patients with neurological
complications associated with HCV infection.
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Hepatitis C virus (HCV) infection affects
approximately 170 million persons world-
wide and is a pandemic 5 times larger than
that of HIV. In the United States and Brazil,
approximately 2% of the population is sero-
positive for HCV (1). The most common
mode of HCV transmission is percutaneous
exposure to contaminated blood, including
situations associated with intravenous drug
use and blood transfusions. HCV infection is
a common cause of chronic liver disease,
cirrhosis, and hepatocellular carcinoma (1).
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In addition to the liver manifestations,
chronic HCV infection may be associated
with a series of extrahepatic manifestations,
such as mixed cryoglobulinemia, membra-
noproliferative glomerulonephritis, autoim-
mune thyroiditis, and lymphoproliferative
disorders. These manifestations result from
lymphoproliferative and/or autoimmune
mechanisms, and occur in 40 to 75% of
patients with chronic HCV infection (2).
The association of HCV infection with
mixed cryoglobulinemia and peripheral neu-
ropathy has been previously reported (3).
However, its pathogenesis is not completely
understood, nor do formal treatment guide-
lines exist. Peripheral neuropathy and de-
tectable serum cryoglobulins appear in ap-
proximately one third of patients with HCV
infection, but HCV-infected patients with
peripheral neuropathy in the absence of se-
rum cryoglobulins have also been described
(3,4). In this report, we present a patient with
chronic HCV infection, cryoglobulinemia,
and peripheral neuropathy.
Case report
A 48-year-old man was referred to the
Disciplina de Neurologia of Hospital das
Clínicas, Universidade Estadual de Campi-
nas, due to hypoesthesia on the lateral side of
the right foot, which progressed to the lower
and upper limbs, accompanied by distal
paresthesias of both legs. The patient denied
arthralgia and Raynaud’s phenomenon. He
had been treated with bromazepam, pred-
nisone, paracetamol, codeine, and carba-
mazepine without symptom relief. His medi-
cal history was unremarkable; he specifical-
ly denied illicit drug use, alcohol abuse,
contact with toxic substances, and diabetes.
He had been smoking approximately 40 ciga-
rettes per day for 20 years. Neurological
examination revealed motor weakness in the
lower right limb (graded as 4 in the general
medical conditions grading - maximum 5).
Areas of anesthesia were found in both hands
and feet. Ankle tendon reflexes were abol-
ished.
Laboratory findings revealed normal
platelet, red and white blood cell counts.
Serum levels of total bilirubin, glucose, elec-
trolytes, creatine, urea nitrogen, alanine ami-
notransferase, aspartate aminotransferase,
alkaline phosphatase, and γ-glutamyl trans-
ferase were all in the normal range. Thyroid
function tests and protein electrophoresis
did not reveal any abnormality. Anti-DNA,
antinuclear, anti-SSA/RO, anti-SSB, anti-
neutrophil cytoplasmic, anti-Jo1, anti-SCL
70, and anti-ENA antibodies and lupus
erythematosus cells were all normal or nega-
tive. C-reactive protein (3.21 mg/dL; normal
<0.5 mg/dL) and rheumatoid factor (219 IU/
mL; normal <20 IU/mL) were increased.
Urine and cerebrospinal fluid analyses were
normal. Serum cryoglobulins were detected
(Hospital das Clínicas in-house method), but
not typed or quantified.
Electromyography showed a severe and
generalized neuropathic impairment mainly
in the lower limbs. The evoked potential
component revealed compromised activity,
predominantly axonal, but myelinic involve-
ment was also present. In addition, asym-
metric nerve conduction was demonstrated
in the lower extremities. These findings were
suggestive of multineuropathy. A biopsy of
the right sural nerve revealed myelinic sheath
reduction and inflammatory infiltrate in the
perineural space. Signs of axonal degenera-
tion were also present (Figure 1).
Serum anti-HCV antibodies detected by
enzyme immunoassay (Abbott AxSYM Anti-
HCV 3.0, Abbott Laboratories, Wiesbaden,
Hessen, Germany) were positive. After this
result, the patient was referred to the Grupo
de Estudo das Hepatites Virais outpatient
clinic at Hospital das Clínicas, Universidade
Estadual de Campinas, for HCV infection
evaluation and follow-up. Serum HCV RNA
was detected by qualitative PCR (Cobas
Amplicor HCV Test v2.0, Roche Molecular
Diagnostic Systems, Branchburg, NJ, USA)
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and HCV genotype 1 was identified. Re-
garding hepatitis B virus (HBV) infection,
anti-HBc antibodies were positive, but
HBsAg, anti-HBs, HBeAg, and anti-HBe
were all negative. Serum HBV DNA was
undetectable by hybridization. Serologies
for HIV, syphilis, and Epstein-Barr virus
were negative. A liver biopsy showed mod-
erate chronic hepatitis. Portal fibrosis with
septa (score F2 by the Metavir scoring sys-
tem) and necroinflammation (grade A2 by
the Metavir scoring system) were present.
The patient was tentatively treated with
amitriptyline, phenytoin, and folic acid. De-
spite treatment, his condition deteriorated:
he became unable to walk and presented
dysesthesia in sock distribution, which was
more pronounced in the distal right leg. Treat-
ment with interferon-α (IFN-α, 3 million
units subcutaneously, three times per week)
and ribavirin (500 mg orally, twice a day)
was initiated. Three months later, the patient
experienced arthralgia in large and small
joints. Seven months after the beginning of
treatment, the neurological symptoms began
to improve and, by the end of treatment (a
total of 48 weeks), serum HCV RNA was
negative. Six months after the end of treat-
ment, the patient had relief of neurological
symptoms and negative HCV RNA, which
characterizes sustained viral response, but
serum cryoglobulins remained positive.
Discussion
The HCV incubation period varies from
2 to 26 weeks (median 6 weeks). Acute
infection is asymptomatic in 60 to 70% of
the patients and 20 to 30% of infected per-
sons develop jaundice. Approximately 15 to
30% of patients exposed to HCV recover
spontaneously, whereas the remaining pa-
tients develop chronic infection. One third
of chronically infected patients present mod-
erate to severe hepatitis within 20 years of
infection. Inflammation and hepatic cell ne-
crosis may lead to bridging fibrosis, and
cirrhosis appears in 15 to 20% of patients
with chronic infection. Antibody tests can
be used to detect HCV exposure but they do
not differentiate between resolved and
chronic infection, a task accomplished with
HCV RNA detection tests, such as PCR (1).
Genetic analysis of HCV revealed the
existence of six different genotypes, which
differ in their genome by up to 35%. Geno-
type 1 is the most common variant found in
the United States and Brazil, but the least
responsive to treatment. HCV genotype 1
infections should be treated with a combina-
tion of IFN or pegylated IFN, and ribavirin
for 48 weeks. Since genotypes 2 and 3 are
more responsive to therapy, the duration of
treatment for these genotypes is 24 weeks
(1).
Essential mixed cryoglobulinemia (EMC)
is a systemic vasculitis disorder character-
ized by deposition of serum cryoprecipitable
(precipitation at temperatures <37ºC) im-
mune complexes in small- and medium-sized
blood vessels. Based on immunoglobulin
composition, EMC has been divided into
type I (exclusively monoclonal), type II (IgM
monoclonal and IgG polyclonal), and type
III (exclusively polyclonal). Type I cryoglo-
bulinemia does not show rheumatoid factor
activity and is usually associated with lym-
phoproliferative disorders, whereas types II
and III are not necessarily associated with
these or other disorders, such as autoim-
mune or chronic liver diseases and viral
Figure 1. Right sural nerve biopsy stained with hematoxylin and eosin. There is an intense
inflammatory infiltrate within the epineurium transverse section (panel A) and reduced
myelin sheath-forming Schwann cells in the longitudinal section (panel B). The arrow shows
the only preserved axon. 400X.
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infections (e.g., Epstein-Barr virus infec-
tions). Types II and III are called mixed
cryoglobulinemias and usually show rheu-
matoid factor activity. Because of high rates
of association between EMC and hepatocel-
lular abnormalities, it is speculated that
hepatotropic viruses, such as HCV, might be
involved in the pathogenesis of the former
(5).
The ability of HCV to cause extrahepatic
manifestations has been demonstrated pre-
viously (1,6). One report has shown serum
cryoglobulins in 36-54% of patients with
chronic hepatitis C (7). Lunel et al. (8) found
serum cryoglobulins in 72 (57%) of 127
HCV-infected patients and in only 4% of
uninfected persons. Approximately one third
of patients with hepatitis C and serum
cryoglobulins have type II cryoglobuline-
mia and two thirds have type III. Another
study has shown that 81 to 90% of patients
with EMC were HCV RNA positive (9). The
mechanism by which HCV elicits cryoglo-
bulin formation is unclear, but may be re-
lated to the persistence of HCV in the cells of
the immune system and/or chronic stimula-
tion of the immune response by HCV. Ge-
netic factors, such as human leukocyte anti-
gens, may also be involved in the pathogen-
esis of HCV-associated cryoglobulinemia.
The majority of patients with cryoglobu-
linemia are asymptomatic. Only 13-30% of
patients are symptomatic and their clinical
presentation varies from mild vasculitis (Ray-
naud phenomenon (20-50%), arthralgia
(20%), weakness (65%), and purpura (10%))
to severe vasculitis (peripheral neuropathy
(15-25%), membranoproliferative glomeru-
lonephritis (30-50%), and systemic vasculi-
tis (8%)) (9,10). The reason for such wide
variation of symptoms and organ involve-
ment is not completely understood.
Sensory and/or motor peripheral neuro-
pathy has been found in up to 9% of patients
with chronic HCV infection (6). HCV-asso-
ciated peripheral neuropathy is mainly re-
lated to axonal damage and cryoglobuline-
mia is usually present (11). Previous studies
have described this peripheral neuropathy as
both a motor and sensory polyneuropathy,
mainly distal, and of subacute onset; al-
though cases of exclusively asymmetrical
sensory neuropathy have also been reported
(12-14). The presence of serum cryoglobulins
is predictive of more severe and widespread
neuropathic involvement (4,11).
In this report, we describe a patient with
HCV-associated cryoglobulinemia and pe-
ripheral neuropathy whose neurological
manifestation was a multineuropathy of in-
sidious progression. A nerve biopsy showed
axonal degeneration and inflammatory infil-
tration in the perineurial space, which is in
accordance with previous reports (11,15).
Peripheral neuropathy usually occurs in
types II and III, rather than in type I, EMC.
Two main pathogenic mechanisms have been
suggested: 1) impairment of the vasa nervor-
um microcirculation by intravascular depos-
its of cryoglobulins, producing ischemia due
to derangement of the microcirculation, and
2) necrotizing vasculitis induced by long-
standing cryoglobulin precipitation, comple-
ment fixation, and rheumatoid factor activ-
ity. Either the vasculitis itself or the vascular
occlusion causes fascicular ischemia, which
ultimately results in axonal degeneration.
Some investigators speculate that the first
mechanism may account for the pattern of
progressive sensory polyneuropathy and the
second for the multineuropathy features (16).
Demyelinating neuropathy, such as the one
seen in this patient, has been reported previ-
ously in few HCV-infected patients. Im-
mune complex deposition on the myelin
sheath or cross-reaction of antibodies against
myelobasic protein may lead to impairment
of myelin function (15).
In HCV-infected patients without cryo-
globulinemia, the most common neurologi-
cal manifestations are mononeuropathy and
multineuropathy (4,11). HCV RNA has been
isolated in homogenates of nerve biopsy
specimens in these patients by in situ PCR
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(11,17). These findings suggest a direct role
of HCV in the pathogenesis of peripheral
neuropathy. Possible mechanisms include a
direct nerve cytopathic effect by HCV or an
immune-mediated mechanism, such as im-
mune complex-induced changes of the
epineurial vessel (11). Another possible
mechanism is a humoral immune response
combined with an imbalanced antigen/anti-
body ratio, resulting in excess of immune
complexes, which, once deposited on the
vessel walls, induce an inflammatory re-
sponse by activation of the complement sys-
tem. These inflammatory processes lead to
lymphocytic and histiocytic infiltrations into
small vessels and ischemic or inflammatory
organ lesions (15).
There are no definitive guidelines for the
treatment of HCV-associated neurological
manifestations. Some therapeutic options are
immunosuppressive agents, such as cortico-
steroids and/or immunomodulating agents,
e.g., IFN and ribavirin (18). Other studies
have also shown clinical improvement of
acute inflammatory episodes following treat-
ment with corticosteroids and cyclophos-
phamide (4,15,19).
IFN is a powerful modulator of the hu-
moral and cellular immune responses; how-
ever, its mechanism of action is poorly un-
derstood. Reduction of viral replication rate
(even without complete or permanent elimi-
nation), inhibition of lymphocyte prolifera-
tion and immunoglobulin synthesis, and im-
provement of immune complex clearance by
enhancing macrophage activity may account
for its therapeutic properties (18). Previous
studies have shown that treatment with IFN
as monotherapy resulted in improvement of
vasculitis-associated symptoms and serum
cryoglobulin levels, but symptoms re-
bounded after treatment discontinuation (20).
In the present report, the patient showed
complete and sustained remission of both
HCV RNA and neurological symptoms after
48 weeks of treatment with IFN-α and
ribavirin. We observed that neurological
symptoms started to improve after 28 weeks
of treatment, when the patient could have
had negative or very low levels of HCV
RNA. Unfortunately, HCV RNA determina-
tion was not performed at that time, but only
at the end of treatment and 6 months later.
Further studies are needed to document HCV
RNA clearance and neurological symptom
improvement.
The management of HCV-associated pe-
ripheral neuropathy should be based on its
severity and on response to treatment. Corti-
costeroids and/or IFN plus ribavirin are the
first options in patients with mild to moder-
ate neuropathy (19). Since chronic corticos-
teroid administration is associated with in-
creased serum cryoglobulin and HCV RNA
levels, this drug should be administered in
low doses and reduced as soon as possible.
In addition, the long-term consequences of
corticosteroid use for liver function of HCV-
infected patients remain unknown and this
class of drugs should be used with caution.
For patients who do not respond to this
initial approach, intravenous immunoglobu-
lins can be considered. Plasmapheresis ap-
pears to be a reasonable option in severe or
refractory cases. Even patients without ac-
tive hepatic disease (normal alanine ami-
notransferase and mild hepatic lesion by
liver biopsy) show improvement of cryoglo-
bulinemia-associated neurological symptoms
when treated with IFN plus ribavirin (20).
HCV infection is widespread throughout
the world and can be associated with extra-
hepatic manifestations, such as the peripher-
al neuropathy case illustrated in this report.
Patients with HCV infection should be in-
vestigated for neurological manifestations
and HCV testing should be performed in
patients with unexplained peripheral neuro-
pathy. Finally, antiviral treatment with IFN
plus ribavirin, corticosteroids, and/or neuro-
modulators may improve the neurological
symptoms and should be considered in such
patients.
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